Takeda Pharmaceutical Company Limited — FY2023 Form 20-F
Reporting period: Fiscal year ended March 31, 2023; filed June 28, 2023. Although the request metadata says “2022 Q4,” this is an annual report, not a quarterly filing. Financial statements are audited and prepared under IFRS, in Japanese yen (JPY).
Business context and key financial metrics
Takeda is a global biopharmaceutical company focused on gastroenterology, rare diseases, plasma-derived therapies (PDT), oncology and neuroscience. It reported one operating segment. Markets outside Japan generated 87.3% of revenue; the U.S. accounted for 52.2%.
| JPY billions, except margins and EPS | FY2022 | FY2023 | Change |
|---|---|---|---|
| Revenue | 3,569.0 | 4,027.5 | +12.8% reported; -0.8% at constant exchange rates (CER) |
| Operating profit | 460.8 | 490.5 | +6.4%; -1.8% CER |
| Operating margin | 12.9% | 12.2% | -0.7 percentage points |
| Profit before tax | 302.6 | 375.1 | +24.0% |
| Net profit | 230.2 | 317.0 | +37.7% |
| Net margin | 6.4% | 7.9% | +1.5 percentage points |
| Basic EPS (JPY) | 147.14 | 204.29 | +38.8% |
| Operating cash flow | 1,123.1 | 977.2 | -145.9 |
| Capital expenditures | 239.9 | 898.7 | +658.8 |
Gross margin was approximately 69.0% in FY2023, versus 69.0% in FY2022, calculated from reported revenue and cost of sales. The filing does not present a single IFRS free-cash-flow figure. Research and development expense was JPY 633.3 billion, up 20.4% reported and 3.5% CER. Selling, general and administrative expense was JPY 997.3 billion, up 12.5% reported and down 0.9% CER.
| Balance sheet and liquidity | As of March 31, 2022 | As of March 31, 2023 |
|---|---|---|
| Cash and cash equivalents (JPY bn) | 849.7 | 533.5 |
| Bonds and loans (JPY bn) | 4,345.4 | 4,382.3 |
| Total assets (JPY bn) | 13,178.0 | 13,957.8 |
| Total equity (JPY bn) | 5,683.5 | 6,354.7 |
| Current assets / current liabilities (JPY bn) | 2,593.6 / 2,145.7 | 2,398.0 / 2,481.9 |
Cash included JPY 125.8 billion temporarily held for third parties. Takeda also had an undrawn JPY 700 billion committed bank facility, available through September 2026, and reported no short-term funding or liquidity shortfall anticipated. Bonds and loans were JPY 4.38 trillion; the company said it complied with its financial covenants and retained investment-grade ratings. The current ratio was approximately 0.97 at year-end. Cash less bonds and loans was approximately JPY 3.85 trillion, excluding lease liabilities.
Material changes versus the prior year
- Reported revenue rose JPY 458.5 billion, but fell 0.8% at CER. A weaker yen materially lifted reported results; the company also noted the prior-year JPY 133.0 billion revenue from the Japan diabetes-portfolio sale to Teijin.
- Core therapeutic-area revenue increased 21.3% reported to JPY 3,572.9 billion. Oncology declined 6.4%, principally as U.S. generic competition reduced VELCADE revenue 74.8% to JPY 27.8 billion.
- Growth included ENTYVIO revenue of JPY 702.7 billion (+34.7% reported; +15.2% CER), PDT immunology of JPY 678.4 billion (+33.8%; +15.3% CER), and neuroscience of JPY 637.7 billion (+32.2%; +12.1% CER). VYVANSE/ELVANSE grew 40.4% reported, with management citing foreign exchange and temporary shortages of competing generic ADDERALL immediate-release products in the U.S.
- Operating profit increased modestly in reported yen but declined at CER. Product amortization and impairment expense rose to JPY 542.4 billion; R&D expense also increased.
- Operating cash flow decreased 13.0%. Cash used in investing rose to JPY 607.1 billion, primarily reflecting intangible-asset payments including the TAK-279 acquisition. Cash used in financing was JPY 709.1 billion, versus JPY 1,070.3 billion in FY2022.
Outlook, risks and unusual items
- Shareholder returns: Takeda stated its intention to pay an annual dividend of JPY 188 per share in FY2024, up from JPY 180 per share historically. The filing describes this as an intention, not a guarantee.
- Patent erosion: U.S. VYVANSE patent protection was scheduled to expire in August 2023, and management anticipated sales declines from generic entry. ENTYVIO faces loss of regulatory exclusivity later in the decade; certain patents are expected to expire in 2032. Generic VELCADE competition had already materially affected oncology revenue.
- Acquisition and pipeline: Takeda acquired Nimbus Lakshmi, owner of TAK-279 rights, for USD 4.0 billion upfront, with two additional USD 1.0 billion sales-based milestones and potential payments to BMS under an assumed settlement. Development, approval and commercialization remain uncertain. TAK-279 was recorded among intangible assets at JPY 534.0 billion at year-end.
- Other product developments: Takeda decided to discontinue global NATPAR/NATPARA manufacturing at the end of 2024 amid supply challenges and an FDA Complete Response Letter. Japan canceled the remaining 141.76 million Nuvaxovid doses under its supply agreement in February 2023.
- Tax contingency: Takeda recorded a JPY 522 million euro provision—equivalent to EUR 522 million—for the Irish tax assessment concerning Shire’s 2014 AbbVie break fee. The assessment is subject to a required rehearing after an earlier ruling favored Irish Revenue.
- Legal and regulatory exposures: Provisions for legal and other disputes were JPY 64.3 billion. More than 6,200 U.S. product-liability lawsuits related to PREVACID and DEXILANT were disclosed. The AbbVie dispute over LUPRON supply had proceeded to a damages trial, with the court decision pending. The company also disclosed ongoing government investigations and other litigation; outcomes and financial effects may be uncertain.
- Other risks: Significant debt and refinancing needs, foreign-exchange exposure, pricing and reimbursement pressure (including U.S. Inflation Reduction Act measures), reliance on suppliers and plasma supply, product-development failures, and potential impairment of goodwill and intangibles. Goodwill and intangible assets totaled JPY 9.06 trillion, or 64.9% of total assets; no goodwill impairment was recorded in FY2023.
- Audit and controls: KPMG issued unqualified opinions on the IFRS financial statements and internal control over financial reporting. The auditor identified estimation of U.S. Medicaid and commercial managed-care rebate provisions as a critical audit matter; the related provision was JPY 293.4 billion.
Important facts for investors to verify
- Separate underlying performance from currency effects: reported revenue rose 12.8%, while CER revenue declined 0.8%.
- Assess the expected pace and financial impact of VYVANSE generic entry and other patent expirations, alongside growth and competitive positioning for ENTYVIO and PDT products.
- Review cash conversion and planned investment after capital expenditures rose to JPY 898.7 billion and cash declined to JPY 533.5 billion; confirm the treatment of third-party cash and lease liabilities.
- Track debt maturities, refinancing costs, covenant headroom and the company’s ability to sustain dividends and fund the TAK-279 program and other pipeline commitments.
- Monitor resolution of the EUR 522 million Irish tax assessment, the AbbVie supply litigation, product-liability cases, and the material rebate estimates highlighted by the auditor.
- Confirm subsequent regulatory, commercial and supply developments, since this annual filing reports FY2023 results and includes some pipeline information current only through May 2023.